Abstract 618P
Background
Vactosertib (TEW-7197), a highly selective and potent inhibitor of TGF-β receptor type 1, combined with PD-1 inhibition could induce immune restoration and enhance anti-tumor responses in patients with microsatellite stable metastatic colorectal cancer (mCRC). MP-VAC-204 is a phase 1b/2a study evaluating the combination of vactosertib with pembrolizumab in previously treated MSS mCRC. Here we report the updated safety and efficacy data of this phase 1b/2a study (NCT03724851).
Methods
Eligible patients were >18 years old with ECOG performance status 0-1 and who had disease progression after treatment with all available therapies including fluoropyrimidine and oxaliplatin or irinotecan. The MSI testing was conducted by local or central tests. Tumor biomarkers including granzyme B+ CD8+T cells were measured in serial tumor samples by multiplex immunofluorescence staining and deconvolution-based immune cell analysis. Circulating proteins, TGF-b, CTGF, PAI-1 and PDGF-AB were evaluated from serial blood samples.
Results
A total of 105 patients (36 in 200mg BID, 30 in 200mg QD, 7 in 200mg TID and 32 in 300mg BID) were enrolled. In all patients (N=105), the overall objective response rate was 13.3% [95% confidence interval (CI), 7.5- 21.4] and median duration of response was 6.0 months (95% CI, 2.9-Not Reached [NR]). Median PFS and OS were 1.3 months (95% CI, 1.2-1.4) and 15.8 months (95% CI, 7.9-NR) respectively. Overall PFS rate at 6 months was 17.1% (95% CI, 10.5-25.7) and overall survival rate at 12 months was 61.0% (95% CI, 51.0-70.3). Rash, headache and decreased appetite were the most frequent treatment emergent adverse events (TEAEs), but all were manageable. No fatal serious TEAEs were observed in any cohort. The levels of TGF-β signaling related circulating cytokines, TGF-b, CTGF, PAI-1, and PDGF-AB/BB were significantly decreased after treatment. Tumor-infiltrating and microenvironmental granzyme B secretion by CD8+ cells were significantly increased after treatment.
Conclusions
Vactosertib combined with pembrolizumab showed anti-tumor activity, prolonged overall survival and manageable safety profiles in patients with MSS mCRC. The phase 2 part is still ongoing.
Clinical trial identification
NCT03724851.
Editorial acknowledgement
We sincerely thank all patients, families, and investigators who participated in this study. The authors thank Merck & Co. staffs for supporting this study.
Legal entity responsible for the study
MedPacto.
Funding
MedPacto.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
622P - Evaluation of the metastatic colorectal cancer score (mCCS) in predicting outcome for patients with RAS wild type metastatic colorectal cancer (mCRC) treated with first-line (1L) panitumumab (PAN) plus FOLFIRI/FOLFOX: Updated interim results of the non-interventional study VALIDATE
Presenter: Marcel Reiser
Session: Poster session 10
623P - VIC regimen (vemurafenib/irinotecan/cetuximab) versus bevacizumab plus chemotherapy as first-line treatment for BRAF V600E-mutated advanced colorectal cancer
Presenter: Yijiao Chen
Session: Poster session 10
624P - Tolerability and safety of vemurafenib, cetuximab combined with camrelizumab for BRAF V600E-mutated /MSS metastatic colorectal cancer
Presenter: Meng Qiu
Session: Poster session 10
625P - Efficacy and safety of the combination of encorafenib and cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: An AGEO real-world multicentre study
Presenter: Claire Gallois
Session: Poster session 10
626P - Mucinous differentiation (MD) as predictor of response in BRAF-V600E mutated metastatic colorectal cancer (mCRC) treated with BRAF inhibitors (BRAFi) combinations
Presenter: Francisco Javier Ros Montana
Session: Poster session 10